Workflow
Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

Core Insights - Milestone Scientific Inc. reported a 25% increase in revenue for Q2 2025, reaching $2.3 million, primarily driven by strong international dental sales which more than doubled year-over-year [2][3] - The company has strengthened its leadership team, appointing Eric Hines as the new CEO and Jason Papes as Senior Vice President, Global Head of Sales and Marketing, to support its growth strategy [2] - The gross margin for Q2 2025 was maintained at 70%, reflecting the high-margin dental business and effective cost management [2] Financial Performance - For Q2 2025, revenues were approximately $2.3 million, up from $1.9 million in Q2 2024, marking an increase of about $470,000 [3] - International revenue for Q2 2025 was approximately $1.0 million, an increase of approximately $524,000 compared to the same period in 2024 [3] - The net loss for Q2 2025 was approximately $(1.5) million, or $(0.02) per share, compared to a net profit of $0.2 million, or $0.00 per share, in Q2 2024 [3] Business Strategy - The company aims to accelerate growth in both dental and medical segments by enhancing its direct sales model, e-commerce platform, and targeted marketing campaigns [2] - In the medical segment, Milestone Scientific is focusing on advancing the adoption of its CompuFlo® Epidural System, having secured Medicare Part B payment rate assignment and initial coverage from commercial insurers [2] - Future plans include broadening federal presence, expanding internationally with new distribution partners, and unlocking potential in both business segments [2] Leadership Changes - Eric Hines, the new CEO, is expected to guide the company through its next growth phase, leveraging his experience in operational excellence [2] - Jason Papes brings a proven track record in global sales strategies, enhancing the company's capabilities in sales and marketing [2] - Shanth Thiyagalingam has joined the Board of Directors, contributing over 20 years of medtech executive experience [2] Cash Position - As of June 30, 2025, the company reported cash and cash equivalents of approximately $1.3 million and working capital of approximately $3.9 million [6]